159 related articles for article (PubMed ID: 24754737)
1. Terminal hypothermic Tau.P301L mice have increased Tau phosphorylation independently of glycogen synthase kinase 3α/β.
Maurin H; Lechat B; Borghgraef P; Devijver H; Jaworski T; Van Leuven F
Eur J Neurosci; 2014 Jul; 40(2):2442-53. PubMed ID: 24754737
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy.
Crespo-Biel N; Theunis C; Borghgraef P; Lechat B; Devijver H; Maurin H; Van Leuven F
Neurobiol Dis; 2014 Jul; 67():119-32. PubMed ID: 24704314
[TBL] [Abstract][Full Text] [Related]
3. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
[TBL] [Abstract][Full Text] [Related]
4. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
Ishizawa T; Sahara N; Ishiguro K; Kersh J; McGowan E; Lewis J; Hutton M; Dickson DW; Yen SH
Am J Pathol; 2003 Sep; 163(3):1057-67. PubMed ID: 12937146
[TBL] [Abstract][Full Text] [Related]
5. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.
Köhler C; Dinekov M; Götz J
Neurobiol Aging; 2013 May; 34(5):1369-79. PubMed ID: 23294633
[TBL] [Abstract][Full Text] [Related]
6. Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy.
Maurin H; Chong SA; Kraev I; Davies H; Kremer A; Seymour CM; Lechat B; Jaworski T; Borghgraef P; Devijver H; Callewaert G; Stewart MG; Van Leuven F
PLoS One; 2014; 9(2):e87605. PubMed ID: 24498342
[TBL] [Abstract][Full Text] [Related]
7. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.
Terwel D; Muyllaert D; Dewachter I; Borghgraef P; Croes S; Devijver H; Van Leuven F
Am J Pathol; 2008 Mar; 172(3):786-98. PubMed ID: 18258852
[TBL] [Abstract][Full Text] [Related]
8. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice.
Xu J; Sato S; Okuyama S; Swan RJ; Jacobsen MT; Strunk E; Ikezu T
FASEB J; 2010 Aug; 24(8):2904-15. PubMed ID: 20354135
[TBL] [Abstract][Full Text] [Related]
9. Tau phosphorylation in hippocampus results in toxic gain-of-function.
Avila J; Gómez de Barreda E; Engel T; Lucas JJ; Hernández F
Biochem Soc Trans; 2010 Aug; 38(4):977-80. PubMed ID: 20658988
[TBL] [Abstract][Full Text] [Related]
10. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β peptide alteration of tau exon-10 splicing via the GSK3β-SC35 pathway.
Chen KL; Yuan RY; Hu CJ; Hsu CY
Neurobiol Dis; 2010 Nov; 40(2):378-85. PubMed ID: 20615469
[TBL] [Abstract][Full Text] [Related]
12. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
13. A 4R tauopathy develops without amyloid deposits in aged cat brains.
Poncelet L; Ando K; Vergara C; Mansour S; Suain V; Yilmaz Z; Reygel A; Gilissen E; Brion JP; Leroy K
Neurobiol Aging; 2019 Sep; 81():200-212. PubMed ID: 31306814
[TBL] [Abstract][Full Text] [Related]
14. Interneuronal transfer of human tau between Lamprey central neurons in situ.
Kim W; Lee S; Jung C; Ahmed A; Lee G; Hall GF
J Alzheimers Dis; 2010; 19(2):647-64. PubMed ID: 20110609
[TBL] [Abstract][Full Text] [Related]
15. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
Terwel D; Lasrado R; Snauwaert J; Vandeweert E; Van Haesendonck C; Borghgraef P; Van Leuven F
J Biol Chem; 2005 Feb; 280(5):3963-73. PubMed ID: 15509565
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.
Haggerty T; Credle J; Rodriguez O; Wills J; Oaks AW; Masliah E; Sidhu A
Eur J Neurosci; 2011 May; 33(9):1598-610. PubMed ID: 21453448
[TBL] [Abstract][Full Text] [Related]
17. Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy.
Buccarello L; Grignaschi G; Castaldo AM; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T
J Alzheimers Dis; 2017; 56(4):1279-1292. PubMed ID: 28157099
[TBL] [Abstract][Full Text] [Related]
18. A mouse model to study tau pathology related with tau phosphorylation and assembly.
Engel T; Lucas JJ; Hernández F; Avila J
J Neurol Sci; 2007 Jun; 257(1-2):250-4. PubMed ID: 17362999
[TBL] [Abstract][Full Text] [Related]
19. Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.
Rockenstein E; Ubhi K; Trejo M; Mante M; Patrick C; Adame A; Novak P; Jech M; Doppler E; Moessler H; Masliah E
BMC Neurosci; 2014 Jul; 15():90. PubMed ID: 25047000
[TBL] [Abstract][Full Text] [Related]
20. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
Boekhoorn K; Terwel D; Biemans B; Borghgraef P; Wiegert O; Ramakers GJ; de Vos K; Krugers H; Tomiyama T; Mori H; Joels M; van Leuven F; Lucassen PJ
J Neurosci; 2006 Mar; 26(13):3514-23. PubMed ID: 16571759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
